HER2

Boehringer flexes staying power of HER2-mutant lung cancer med

Tyrosine kinase inhibitor zongertinib has an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said.

Zoey Becker Apr 28, 2025 9:00am

part ways switch off track cancel end path

Eisai's abandoned Enhertu challenger set to live on at BlissBio

Mar 21, 2025 7:20am

Roche companion test moves into HER2-ultralow breast cancer

Feb 4, 2025 12:00pm

OS' drug stopped lung cancer from returning in 3rd of patients

Jan 15, 2025 9:55am

A series of dice with a bag on them illustrating cost cuts

Carisma axes sole clinical candidate, lays off 34% of staff

Dec 9, 2024 10:58am

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months

Sep 16, 2024 3:00am